CD276 immature glycosylation drives colorectal cancer aggressiveness and T cell mediated immune escape.

ABSTRACT:

Background

Colorectal cancer (CRC) progression is fuelled by immune evasion, yet the underlying molecular mechanisms remain to be fully characterized. CD276 (B7-H3), an immune checkpoint glycoprotein frequently overexpressed in aggressive tumors, is extensively modified by glycosylation, a process known to regulate protein stability, localization, and immune interactions. However, its glycosylation-dependent functions in CRC remain unclear.

Methods

TCGA Transcriptomic data were analysed to identify glycogene alterations linked to patient prognosis. The O-glycome of advanced CRC and normal mucosa was profiled by mass spectrometry. CD276 expression and glycosylation were examined in primary tumors, lymph nodes, and metastases by immunohistochemistry, proximity ligation assays,

SUBMITTER: Soares J 

PROVIDER: S-EPMC12903257 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature